AbbVie Reports Strong Q1 2026 Financial Results Exceeding Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy ABBV?
Source: PRnewswire
- Strong Performance: AbbVie reported net revenues of $15.002 billion for Q1 2026, a 12.4% increase year-over-year, demonstrating robust growth in immunology and neuroscience, which solidifies its market position.
- Upgraded EPS Guidance: The company raised its adjusted diluted EPS guidance for 2026 to $14.08-$14.28, despite including $744 million in acquisition-related R&D expenses, reflecting management's confidence in future performance.
- Increased R&D Investment: R&D expenses reached $2.472 billion in Q1, a 19.6% increase, indicating AbbVie's ongoing commitment to innovative drug development aimed at driving long-term growth and enhancing market competitiveness.
- Diverse Product Line Performance: Key products like Skyrizi and Rinvoq saw sales growth of 29.3% and 15.1%, respectively, highlighting AbbVie's strong performance in the rapidly evolving biopharmaceutical market and enhancing the diversity and adaptability of its product portfolio.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABBV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise
18 Analyst Rating
12 Buy
6 Hold
0 Sell
Moderate Buy
Current: 197.380
Low
223.00
Averages
252.00
High
289.00
Current: 197.380
Low
223.00
Averages
252.00
High
289.00
About ABBV
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AbbVie Q1 Earnings Beat Expectations with Strong Revenue Growth
- Significant Revenue Growth: AbbVie's Q1 revenue reached $15 billion, reflecting a 12.4% year-over-year increase, exceeding market expectations by $280 million, indicating strong performance in the immunology sector.
- Immunology Product Performance: Global net revenues from the immunology portfolio were $7.290 billion, up 16.4%, with Skyrizi generating $4.483 billion, Rinvoq $2.119 billion, and Humira $688 million, demonstrating the driving force of new products in the company's growth.
- Adjusted EPS Guidance Raised: AbbVie raised its adjusted diluted EPS guidance for 2026 from $13.96-$14.16 to $14.08-$14.28, despite accounting for a $0.41 per share impact from acquisition-related expenses, reflecting the company's confidence in future performance.
- Competitive Market Advantage: AbbVie's Rinvoq outperformed Humira in a head-to-head study for rheumatoid arthritis, further solidifying its competitive position in the immunology market and indicating potential for future growth.
See More
AbbVie Q1 Earnings Expected to Show Recovery
- Earnings Growth Expectation: AbbVie is projected to report Q1 EPS growth of 8.5% year-over-year to $2.67, with revenue expected at $14.72 billion, reflecting a 10.3% increase, aligning with the company's own guidance and indicating a recovery in profitability.
- Long-Term Growth Drivers: Analysts believe that strong performances from Skyrizi and Rinvoq will offset the decline from Humira, with long-term earnings projections indicating a compound annual growth rate (CAGR) in the upper single digits, suggesting stable growth for the company moving forward.
- Sales Forecast: Management anticipates a total sales growth of 9.5% for the year, with net revenues around $67 billion, an adjusted gross margin exceeding 84%, and an adjusted operating margin ratio of approximately 48.5%, further solidifying the company's market position.
- Dividend Growth Recovery: Analysts noted that AbbVie's recent annual dividend increase of 5.48% suggests a stabilization in growth following a recent slowdown, enhancing investor confidence in the company's future prospects.
See More
AbbVie Raises Full-Year Earnings Outlook Amid Strong Drug Performance
- Earnings Beat: AbbVie reported $15 billion in revenue for Q1 2026, reflecting a ~12% year-over-year growth that exceeded consensus estimates by $280 million, showcasing the strong performance of its newer drugs Skyrizi and Rinvoq, which offset declines from Humira.
- Significant Drug Contributions: Skyrizi and Rinvoq generated $4.5 billion and $2.1 billion in global sales, respectively, with year-over-year growth rates of ~31% and ~23%, enhancing the company's competitive position and laying a solid foundation for future revenue growth.
- Humira Sales Decline: Once the world's best-selling drug, Humira's revenue fell to $688 million, down ~39% year-over-year, primarily due to competition from biosimilars, indicating the need for AbbVie to accelerate the market introduction of new products to stabilize revenue.
- Profitability Analysis: AbbVie's adjusted gross margin and operating margin stood at 83.6% and 40.8%, down from 84.1% and 42.3% in the prior year, while adjusted diluted EPS of $2.65, despite an ~8% year-over-year increase, missed consensus by $0.02, reflecting ongoing profitability pressures.
See More
AbbVie Earnings Analysis and Growth Outlook
- Earnings Performance: AbbVie reported a non-GAAP EPS of $2.65, missing expectations by $0.02, while revenue reached $15 billion, exceeding market forecasts by $280 million, indicating resilience in revenue growth despite EPS shortfall.
- Product Competitiveness: AbbVie's Rinvoq outperformed Humira in a head-to-head study for rheumatoid arthritis, enhancing the competitiveness of its portfolio and potentially driving future market share growth in a lucrative therapeutic area.
- Investment Rating: Analysts have upgraded AbbVie’s rating, although with caveats, reflecting ongoing market confidence in its growth potential while cautioning investors to remain aware of potential risks that could impact performance.
- Dividends and Potential: AbbVie’s dividend policy, combined with its ability to renew its product portfolio, showcases significant growth potential, appealing to investors seeking stable returns in a dynamic pharmaceutical landscape.
See More
AbbVie Reports Strong Quarterly Earnings Driven by Immunology Drugs
- New Drug Sales Surge: AbbVie's immunology drugs Skyrizi and Rinvoq drove better-than-expected quarterly revenue and profit, with Skyrizi achieving $4.48 billion in sales for Q1, a 30.9% increase year-over-year, surpassing Wall Street's $4.41 billion estimate, indicating strong market acceptance and profitability of new products.
- Humira Sales Decline: Following Humira's loss of U.S. patent exclusivity in 2023, global sales fell 38.6% to $688 million, slightly missing analysts' expectations of $696.5 million, reflecting the challenges and competitive pressures the company faces during its transition.
- Neuroscience Business Outperformance: AbbVie's neuroscience portfolio saw a 26% revenue increase to $2.88 billion, with Botox Therapeutic sales exceeding $1 billion for the first time in a quarter, showcasing strong demand and market potential in this sector.
- Full-Year Earnings Guidance Raised: The company raised its full-year adjusted earnings forecast to a range of $14.08 to $14.28 per share from the previous $13.96 to $14.16, indicating management's confidence in future performance and positive outlook on market demand.
See More
AbbVie Earnings Analysis and Growth Outlook
- Earnings Performance: AbbVie's non-GAAP EPS of $2.65 fell short by $0.02, yet the revenue of $15 billion exceeded expectations by $280 million, indicating resilience in revenue growth despite earnings pressure.
- Product Competitiveness: AbbVie's Rinvoq outperformed Humira in a head-to-head study for rheumatoid arthritis, further solidifying its competitive position in the biopharmaceutical market and laying the groundwork for future market share growth.
- Investment Recommendation: Despite some earnings pressure reflected in the report, analysts still view AbbVie's stock as a buy, particularly in light of its portfolio renewal and potential dividend yields, showcasing long-term investment appeal.
- Growth Potential: AbbVie's strategy of renewing its product portfolio, combined with strong revenue performance, suggests significant growth potential moving forward, especially driven by ongoing innovation and market demand in the biopharmaceutical sector.
See More
AbbVie Q1 Earnings Beat Expectations with Strong Revenue Growth
- Significant Revenue Growth: AbbVie's Q1 revenue reached $15 billion, reflecting a 12.4% year-over-year increase, exceeding market expectations by $280 million, indicating strong performance in the immunology sector.
- Immunology Product Performance: Global net revenues from the immunology portfolio were $7.290 billion, up 16.4%, with Skyrizi generating $4.483 billion, Rinvoq $2.119 billion, and Humira $688 million, demonstrating the driving force of new products in the company's growth.
- Adjusted EPS Guidance Raised: AbbVie raised its adjusted diluted EPS guidance for 2026 from $13.96-$14.16 to $14.08-$14.28, despite accounting for a $0.41 per share impact from acquisition-related expenses, reflecting the company's confidence in future performance.
- Competitive Market Advantage: AbbVie's Rinvoq outperformed Humira in a head-to-head study for rheumatoid arthritis, further solidifying its competitive position in the immunology market and indicating potential for future growth.
See More
AbbVie Q1 Earnings Expected to Show Recovery
- Earnings Growth Expectation: AbbVie is projected to report Q1 EPS growth of 8.5% year-over-year to $2.67, with revenue expected at $14.72 billion, reflecting a 10.3% increase, aligning with the company's own guidance and indicating a recovery in profitability.
- Long-Term Growth Drivers: Analysts believe that strong performances from Skyrizi and Rinvoq will offset the decline from Humira, with long-term earnings projections indicating a compound annual growth rate (CAGR) in the upper single digits, suggesting stable growth for the company moving forward.
- Sales Forecast: Management anticipates a total sales growth of 9.5% for the year, with net revenues around $67 billion, an adjusted gross margin exceeding 84%, and an adjusted operating margin ratio of approximately 48.5%, further solidifying the company's market position.
- Dividend Growth Recovery: Analysts noted that AbbVie's recent annual dividend increase of 5.48% suggests a stabilization in growth following a recent slowdown, enhancing investor confidence in the company's future prospects.
See More
AbbVie Raises Full-Year Earnings Outlook Amid Strong Drug Performance
- Earnings Beat: AbbVie reported $15 billion in revenue for Q1 2026, reflecting a ~12% year-over-year growth that exceeded consensus estimates by $280 million, showcasing the strong performance of its newer drugs Skyrizi and Rinvoq, which offset declines from Humira.
- Significant Drug Contributions: Skyrizi and Rinvoq generated $4.5 billion and $2.1 billion in global sales, respectively, with year-over-year growth rates of ~31% and ~23%, enhancing the company's competitive position and laying a solid foundation for future revenue growth.
- Humira Sales Decline: Once the world's best-selling drug, Humira's revenue fell to $688 million, down ~39% year-over-year, primarily due to competition from biosimilars, indicating the need for AbbVie to accelerate the market introduction of new products to stabilize revenue.
- Profitability Analysis: AbbVie's adjusted gross margin and operating margin stood at 83.6% and 40.8%, down from 84.1% and 42.3% in the prior year, while adjusted diluted EPS of $2.65, despite an ~8% year-over-year increase, missed consensus by $0.02, reflecting ongoing profitability pressures.
See More
AbbVie Earnings Analysis and Growth Outlook
- Earnings Performance: AbbVie reported a non-GAAP EPS of $2.65, missing expectations by $0.02, while revenue reached $15 billion, exceeding market forecasts by $280 million, indicating resilience in revenue growth despite EPS shortfall.
- Product Competitiveness: AbbVie's Rinvoq outperformed Humira in a head-to-head study for rheumatoid arthritis, enhancing the competitiveness of its portfolio and potentially driving future market share growth in a lucrative therapeutic area.
- Investment Rating: Analysts have upgraded AbbVie’s rating, although with caveats, reflecting ongoing market confidence in its growth potential while cautioning investors to remain aware of potential risks that could impact performance.
- Dividends and Potential: AbbVie’s dividend policy, combined with its ability to renew its product portfolio, showcases significant growth potential, appealing to investors seeking stable returns in a dynamic pharmaceutical landscape.
See More
AbbVie Reports Strong Quarterly Earnings Driven by Immunology Drugs
- New Drug Sales Surge: AbbVie's immunology drugs Skyrizi and Rinvoq drove better-than-expected quarterly revenue and profit, with Skyrizi achieving $4.48 billion in sales for Q1, a 30.9% increase year-over-year, surpassing Wall Street's $4.41 billion estimate, indicating strong market acceptance and profitability of new products.
- Humira Sales Decline: Following Humira's loss of U.S. patent exclusivity in 2023, global sales fell 38.6% to $688 million, slightly missing analysts' expectations of $696.5 million, reflecting the challenges and competitive pressures the company faces during its transition.
- Neuroscience Business Outperformance: AbbVie's neuroscience portfolio saw a 26% revenue increase to $2.88 billion, with Botox Therapeutic sales exceeding $1 billion for the first time in a quarter, showcasing strong demand and market potential in this sector.
- Full-Year Earnings Guidance Raised: The company raised its full-year adjusted earnings forecast to a range of $14.08 to $14.28 per share from the previous $13.96 to $14.16, indicating management's confidence in future performance and positive outlook on market demand.
See More
AbbVie Earnings Analysis and Growth Outlook
- Earnings Performance: AbbVie's non-GAAP EPS of $2.65 fell short by $0.02, yet the revenue of $15 billion exceeded expectations by $280 million, indicating resilience in revenue growth despite earnings pressure.
- Product Competitiveness: AbbVie's Rinvoq outperformed Humira in a head-to-head study for rheumatoid arthritis, further solidifying its competitive position in the biopharmaceutical market and laying the groundwork for future market share growth.
- Investment Recommendation: Despite some earnings pressure reflected in the report, analysts still view AbbVie's stock as a buy, particularly in light of its portfolio renewal and potential dividend yields, showcasing long-term investment appeal.
- Growth Potential: AbbVie's strategy of renewing its product portfolio, combined with strong revenue performance, suggests significant growth potential moving forward, especially driven by ongoing innovation and market demand in the biopharmaceutical sector.
See More
